Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children (NCT06070350)
Massive Transfusion in Children: a Platform RCT of Whole Blood Compared to Component Therapy and Tranexamic Acid to Placebo in Life-threatening Traumatic Bleeding
🩺 Plain-English Summary (8th-Grade Level)
The MATIC-2 is a multicenter clinical trial enrolling children who are less than 18 years of age with hemorrhagic shock potentially needing significant blood transfusion. The primary objective of the clinical trial is to determine the effectiveness of Low Titer Group O Whole Blood (LTOWB) compared to component therapy (CT), and Tranexamic Acid (TXA) compared to placebo in decreasing 24-hour all-cause mortality in children with traumatic life threatening hemorrhage.
Who can join: Review the eligibility criteria below.
Location: University of Arizona — Tucson, Arizona
Age range: Not specified to 17 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (23 Sites)
- University of Arizona — Tucson, Arizona
- Arkansas Children's Hospital — Little Rock, Arkansas
- University of California Davis — Sacramento, California
- Children's National Hospital — Washington D.C., District of Columbia
- Emory University-Arthur M. Blank Hospital — Atlanta, Georgia
- Emory University-Scottish Rite Hospital — Atlanta, Georgia
- Tulane School of Medicine — New Orleans, Louisiana
- University of Mississippi Medical Center — Jackson, Mississippi
- Washington University of St. Louis — St Louis, Missouri
- University of New Mexico — Albuquerque, New Mexico
- Wake Forest University Health Sciences — Wake Forest, North Carolina
- Nationwide Children's Hospital — Columbus, Ohio
- Oregon Health and Science University — Portland, Oregon
- Children's Hospital of Pittsburgh of UPMC — Pittsburgh, Pennsylvania
- LeBonheur Children's Hospital — Memphis, Tennessee
- Vanderbilt University Medical Center — Nashville, Tennessee
- The University of Texas Southwestern Medical Center — Dallas, Texas
- Baylor College of Medicine — Houston, Texas
- Children's Memorial Hermann Hospital — Houston, Texas
- University of Texas Health Science Center at San Antonio — San Antonio, Texas
- Primary Children's Hospital — Salt Lake City, Utah
- University of Washington Harborview — Seattle, Washington
- Medical College of Wisconsin — Milwaukee, Wisconsin
📞 Contact the Study Coordinator
Phone: (412) 383-2340
Email: tdb33@pitt.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hemorrhagic Shock
- REVIVE: Reducing Exsanguination Via In-Vivo Expandable Foam — Birmingham, Alabama
Explore by condition: All Hemorrhagic Shock clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.